No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US OptionsDetailed Quotes
SWTX250117P30000
- 0.86
- -0.33-27.73%
15min DelayClose Jan 10 16:00 ET
1.60High0.86Low
1.20Open1.19Pre Close236 Volume343 Open Interest30.00Strike Price31.67KTurnover248.27%IV32.23%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier7DDays to Expiry0.86Extrinsic Value100Contract SizeAmericanOptions Type-0.1109Delta0.0128Gamma46.49Leverage Ratio-0.1983Theta-0.0010Rho-5.16Eff Leverage0.0113Vega
Intraday
- 5D
- Daily
News
Watching SpringWorks Therapeutics; Shares Trading Higher, Traders Circulate M&A Blog Comments Suggesting The Co Has Received Takeover Interest
SpringWorks Therapeutics Price Target Lowered to $78 From $80 at Guggenheim
SpringWorks Therapeutics Price Target Cut to $78.00/Share From $80.00 by Guggenheim
Guggenheim Initiates SpringWorks Therapeutics(SWTX.US) With Buy Rating, Announces Target Price $78
BofA Securities Maintains SpringWorks Therapeutics(SWTX.US) With Buy Rating, Cuts Target Price to $55
Express News | SpringWorks Therapeutics Inc : BofA Global Research Cuts Price Objective to $55 From $58